Core Insights - Zhonghui Biotech (02627.HK) experienced a significant stock price increase of 158% on its debut, closing at HKD 33.28 per share, resulting in a total market capitalization of HKD 13.09 billion [1] Company Overview - Zhonghui Biotech focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technological methods [1] - The company has two core products: a quadrivalent influenza virus subunit vaccine and a developing lyophilized human rabies vaccine [1] IPO Performance - The IPO of Zhonghui Biotech was highly successful, achieving over 4,000 times oversubscription in the public offering in Hong Kong, with a total subscription amount exceeding HKD 200 billion [1] - This oversubscription made Zhonghui Biotech the top performer in the 18A biotech sector of the Hong Kong stock market for the year [1]

中国经济网北京8月11日讯江苏中慧元通生物科技股份有限公司(以下简称"中慧生物"，02627.HK)今日 在港交所上市。截至今日收盘，中慧生物报33.28港元，涨幅157.98%。 | 發售股份及股本 | | | --- | --- | | 發售股份數目 | 33,442,600 | | 香港公開發售的發售股份數目(重新分配後) | 3,996,000 | | 國際發售的發售股份數目(重新分配後) | 29,446,600 | | 於上市時已發行股份數目 | 393,442,600 | 中慧生物的联席保荐人、整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人为中信证券 (香港)有限公司、中信里昂证券有限公司、招银国际融资有限公司，联席账簿管理人兼联席牵头经办人 为利弗莫尔证券有限公司、富德证券有限公司、雅利多证券有限公司、中银国际亚洲有限公司、工银国 际证券有限公司。 中慧生物的最终发售价为12.90港元，所得款项总额为431.4百万港元，扣除按最终发售价计算的估计应 付上市开支48.7百万港元，所得款项净额为382.7百万港元。 | 價格資料 | | | --- | --- | | 最終發售價 | ...

Group 1 - The company, Zhonghui Biotechnology-B (02627), announced the results of its share allocation, with a total global offering of 33.4426 million shares [1] - The Hong Kong public offering accounted for 11.95% of the total shares, while the international offering made up 88.05% [1] - The final offer price was set at HKD 12.9 per share, resulting in net proceeds of approximately HKD 383 million from the global offering [1] Group 2 - The Hong Kong public offering was oversubscribed by 4,007.64 times, indicating strong demand from local investors [1] - The international offering had a subscription rate of 0.99 times, reflecting a more moderate interest from international investors [1] - The H-shares are expected to commence trading on the Hong Kong Stock Exchange on August 11, 2025, at 9:00 AM Hong Kong time [1]

Core Viewpoint - Zhonghui Biotech-B (02627.HK) announced a global offering of 33,442,600 H-shares at a final offer price of HKD 12.90 per share, resulting in a net proceeds of HKD 383 million [1] Summary by Categories Global Offering Details - The Hong Kong public offering accounted for 11.95% of the total global offering, with a subscription rate of 4,007.64 times [1] - The international offering represented 88.05% of the total global offering, with a subscription rate of 0.99 times [1] Trading Information - Assuming the global offering becomes unconditional on August 11, 2025, the H-shares are expected to commence trading on the Hong Kong Stock Exchange at 9:00 AM (Hong Kong time) on the same day [1] - H-shares will be traded in board lots of 200 shares, with the stock code being 2627 [1]

Group 1 - The company Zhonghui Biotech-B (02627) announced the results of its share placement, with a total global offering of 33.4426 million shares [1] - The Hong Kong public offering accounted for 11.95% of the total, while the international offering made up 88.05% [1] - The final offer price was set at HKD 12.9 per share, resulting in net proceeds of approximately HKD 383 million from the global offering [1] Group 2 - The Hong Kong public offering was oversubscribed by 4007.64 times, indicating strong demand [1] - The international offering had a subscription rate of 0.99 times, reflecting a lower demand compared to the public offering [1] - The H-shares are expected to commence trading on the Hong Kong Stock Exchange on August 11, 2025, at 9:00 AM Hong Kong time [1]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表聲明，並明確表示概不 會就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公告不得直接或間接於或向美國（包括其領土及屬地、美國任何州以及哥倫比亞特區）發佈、 刊發或派發。本公告並不構成或組成在美國境內或於任何其他司法權區購買或認購發售股份的 任何要約或招攬的一部分。發售股份並無亦不會根據《1933年美國證券法》（經不時修訂）（「美 國證券法」）或美國任何州或其他司法權區的證券法登記。發售股份不得在美國境內提呈發售、 出售、質押或以其他方式轉讓，除非已根據美國證券法及《1940年美國投資公司法》（經修訂） （「美國投資公司法」）的登記規定獲豁免，並已符合任何州的適用證券法。發售股份根據美國證 券法S規例在美國境外向非美籍人士投資者或並非為美籍人士或為其利益進行收購的投資者提 呈發售及出售。發售股份不會在美國公開發售。 本公告僅作說明用途，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。 潛在投資者於決定是否投資所提 ...

Group 1 - The company Zhonghui Biotech-B (02627) is set to be listed in Hong Kong on August 11, with an initial offering price of HKD 12.9 per share [1] - As of the close, the dark trading by Livermore Securities shows a price of HKD 33.88, representing an increase of 162.64% from the IPO price [1] - Each lot consists of 200 shares, resulting in a profit of HKD 4,196 per lot, excluding transaction fees [1] Group 2 - The trading data indicates a price range with the highest bid at HKD 34.33 and the lowest at HKD 33.88, reflecting significant trading activity [3] - The MACD analysis shows a positive trend with a MACD value of 0.040, indicating potential upward momentum in the stock price [4]

Group 1 - The company Zhonghui Biotech-B (02627) will be listed in Hong Kong on August 11 (Monday) [1] - As of the close, Livermore Securities' dark trading shows a price of HKD 33.88, which is an increase of 162.64% from the offering price of HKD 12.9 [1] - Each lot consists of 200 shares, resulting in a profit of HKD 4,196 per lot, excluding transaction fees [1] Group 2 - The trading data indicates a price range with the highest bid at HKD 34.33 and the lowest at HKD 12.90 [3] - The trading volume at the price of HKD 33.88 was 40 shares, with a significant volume of 168.99% change noted [3][4] - The MACD indicator shows a positive trend with values of 0.040 for MACD, 0.164 for DIF, and 0.144 for DEA [4]

本文源自：金融界AI电报 利弗莫尔证券承销香港IPO新股中慧生物-B暗盘上涨近150%报32.2港元/股，此前一度上涨近170%。中 慧生物-B每手200股，不计手续费，每手赚近3800港元。 ...

Group 1 - The core point of the article is that the stock of Zhonghui Biotech-B surged nearly 150% in the dark market, currently priced at 32.1 HKD, following a delay in its listing due to heavy rain [2] - The initial listing date was postponed from August 8 to August 11, 2025, when the shares are expected to start trading on the Hong Kong Stock Exchange [2]